Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4)

Link copied
Case Copied 21 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2021] FCA 416

File numbers: NSD 121 of 2012
NSD 837 of 2015
Judgment of: YATES J
Date of judgment: 27 April 2021
Catchwords: PRACTICE AND PROCEDURE – application for additional discovery
Legislation:

National Health Act 1953 (Cth) s 99ACB

Federal Court Rules 2011 (Cth) rr 20.11, 20.15

Federal Court of Australia Act 1976 (Cth) s 37M

Cases cited:

Benjoy Berry v CCL Secure Pty Ltd [2020] HCA 27; 381 ALR 427

Malec v JC Hutton Pty Ltd [1990] HCA 20; 169 CLR 638

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230

Sellars v Adelaide Petroleum NL [1994] HCA 4; 179 CLR 332

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 64
Date of hearing: 8 March 2021
Counsel for the Applicants: Mr J Hutton
Solicitors for the Applicants: Jones Day
Counsel for the Respondents: Mr P Knowles
Solicitors for the Respondents: Corrs Chambers Westgarth

ORDERS

NSD 121 of 2012

BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Applicant/First Appellant

BRISTOL-MYERS SQUIBB COMPANY

Second Applicant/Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

First Respondent

COMMONWEALTH OF AUSTRALIA

Other

ORDER MADE BY:

YATES J

DATE OF ORDER:

27 APRIL 2021

THE COURT ORDERS THAT:

1.The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


ORDERS

NSD 837 of 2015
BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Applicant/First Appellant

BRISTOL-MYERS SQUIBB COMPANY

Second Applicant/Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

First Respondent

COMMONWEALTH OF AUSTRALIA

Other

ORDER MADE BY:

YATES J

DATE OF ORDER:

27 APRIL 2021

THE COURT ORDERS THAT:

1.The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

YATES J:

INTRODUCTION

  1. This is an application for additional discovery made in proceedings NSD 121/2012 and NSD 837/2015 in which the Commonwealth of Australia (the Commonwealth) has applied to enforce various undertakings as to damages given by Otsuka Pharmaceutical Co. Ltd, and Bristol-Myers Squibb Company (together, Otsuka/BMS).  Separately, Generic Health Pty Ltd (Generic Health) has applied to enforce these undertakings. 

  2. The background to the enforcement applications is explained in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230. For present purposes, the relevant facts include the following.

  3. On or about 29 November 2011, Generic Health applied to have its aripiprazole products listed…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] FCA 416
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company filed an interlocutory application for additional discovery against Generic Health Pty Ltd. The dispute arose from a broader litigation concerning patent rights and infringement in the pharmaceutical sector. The applicants sought additional documents from the respondent to further their case.

The primary legal issue before the Court was whether the applicants were entitled to the additional discovery sought, given the existing discovery process and the justification provided for the additional discovery. The Court was tasked with determining whether the need for the additional documents was urgent, necessary, and relevant to the issues in the proceeding. The Court also considered the balance of convenience and the potential prejudice to the respondent if the additional discovery was granted.

The Court dismissed the application for additional discovery. The reasoning included that the applicants had not demonstrated sufficient urgency or necessity for the additional documents. The Court found that the existing discovery process had already provided ample information to the applicants and that the additional discovery sought was not strictly necessary for the litigation. The Court further noted that granting the application could potentially prejudice the respondent, who had already provided significant information. Consequently, the Court found that the balance of convenience lay in favour of the respondent.

The final orders of the Court were that the interlocutory application for additional discovery be dismissed, with costs. The costs were to be borne by the applicants, reflecting the Court's decision on the balance of convenience and the lack of sufficient justification for the additional discovery. The entry of orders was in accordance with Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established